



TO:

Nebraska Healthcare Providers, Laboratories, Public Health

FROM: Thomas J. Safranek, M.D. Jeff Hamik M.S.

State Epidemiologist Vector-Borne Disease Epidemiologist

402-471-2937 402-471-1374 PHONE 402-471-3601 FAX

Thomas Williams, M.D. Chief Medical Officer

Director, Division of Public Health


Department of Health and Human Services

**RE:** Summertime Infectious Disease Update: West Nile Virus

DATE: May 29, 2018

## West Nile Virus (WNV)

WNV first arrived in the US in New York City in 1999, and remains an important public health issue for the nation and especially for Nebraska. Since its arrival in Nebraska in 2002, Nebraska has reported a total of 3,736 persons with WNV (68 in 2017) placing our state's rate in the top five nationally. *Culex* species mosquitoes are an excellent WNV vector and are well-established as a resident mosquito throughout our state. Since 2000, Nebraska has tracked WNV in the *Culex* mosquito population through a well-established protocol of trapping and testing mosquito pools. Since its inception, a total of 43,406 *Culex* mosquito pools have been tested, of which 3,543 (8.2%) were positive. For the current 2018 WNV season, surveillance will begin the last weekend in May and go through the end of September.



Human WNV infections follow in the wake of positive mosquito pools, typically beginning in mid-July, peaking around Labor Day, and disappearing around mid-September. The majority of WNV-infected persons (approximately 80%) are asymptomatic. Those who develop symptoms have an incubation period of 3-14 days. Symptoms include: fever, headache, fatigue, skin rash on the trunk of the body, swollen lymph glands, and eye pain. At the time of symptom onset, the viremia has usually resolved and the patient is seropositive for IgM antibodies. Infected persons appear to develop permanent immunity, and cannot be re-infected.

## **Laboratory testing:**

Patients suspected of WNV infection should be tested for IgM and IgG antibodies to WNV. These tests are widely available at commercial labs. If neuroinvasive WNV is suspected, testing can be performed at the Nebraska Public Health Lab (NPHL) at DHHS' expense, provided the following criteria are met:

- The person has signs and symptoms consistent with neuroinvasive (meningitis, encephalitis, acute flaccid paralysis, etc.) WNV disease.
- The specimen is accompanied by a completed NPHL requisition http://www.nphl.org/documents/500005%20NPHL%20Special%20Micro%20ReqMay2018.pdf
- The sample collection date is between June 1 and October 31.
- The submitted specimen must include a CSF for WNV IgM antibody testing. However, it is preferred that the CSF specimen be paired with a serum specimen for WNV IgM/IgG antibody testing.
- Testing of serum specimens without a concurrent or prior CSF specimen requires pre-authorization: call 402-471-2937.

## **WNV Test Interpretation Guidelines**

- Testing (+) for IgM and (-) for IgG in an acute specimen is consistent with acute WNV infection.
- Testing (+) for IgG and (-) for IgM is consistent with infection in the distant past.
- CSF which tests (+) for IgM is consistent with acute meningitis/encephalitis.
- Patients testing (+) for both IgM and IgG antibodies on an initial specimen need a "convalescent" serum (collected at least 14 days following the initial specimen).
- Stable antibody titers on acute and convalescent specimens suggest infection in the distant past. Rising IgM and IgG titers between the acute and the convalescent specimens suggest acute infection. A fourfold rise in titer at the same laboratory at the same time is generally considered indicative of recent infection. Some laboratories may save acute specimens for potential paired convalescent testing. Consultation with your laboratory is recommended.

Tests	Results	Interpretation
IgM	negative	Antibody not detected = not a case of WNV
IgG	negative	
IgM	negative	Infection at undetermined time = past infection
IgG	positive	
IgM	positive	Evidence of recent or current infection
IgG	negative	
IgM	positive	Evidence of recent or current infection*; further
IgG	positive	testing necessary‡
IgM	indeterminate	Inconclusive
IgG	negative	‡request convalescent serum

<sup>\*</sup>Note that some individuals may have persisting antibodies from the previous WNV season; ‡ Paired acute and convalescent serum samples may be useful for demonstration of seroconversion.